It reversed PD-1-mediated T-cell inhibition, inhibited VEGF-driven endothelial proliferation, and induced potent ADCC and ADCP in killing PD-L1<sup>+</sup> tumor cells. The gene discussed is VEGFA; the disease is neoplasm.